Tim Schmid

New Capabilities

Leading J&J's medical device growth strategy, including vision

For a decade, patients choosing premium lenses during cataract surgery have faced a trade-off: better range of vision, but dimmer, lower-contrast sight—especially in low light. On March 12, 2026, the Food and Drug Administration approved Johnson & Johnson's TECNIS PureSee, the first extended depth of focus lens cleared in the United States without a warning for loss of contrast sensitivity. In clinical trials, 97% of patients reported no bothersome visual disturbances like halos or glare.

Updated 5 days ago